Sign In
Buy ARGX
$813.14
+10.97 (+1.37%)
At Close: Jun 03, 2026
argenx SE (ARGX) Q4 2025 Earnings Call Transcript
12:57pm, Thursday, 26'th Feb 2026
argenx SE (ARGX) Q4 2025 Earnings Call Transcript
Argenx Touts Positive Phase 3 Eye Disease Study Results
09:01am, Thursday, 26'th Feb 2026
Argenx SE (NASDAQ: ARGX) on Thursday announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG).
Artisan Global Discovery Fund Q4 2025 Winners, Laggards, Buys & Sells
07:30am, Thursday, 26'th Feb 2026
The portfolio generated strong absolute returns in Q4 and 2025 but trailed the MSCI All Country World Small Mid Index over each period. Stock selection in health care was the strongest contributor to
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
01:00am, Thursday, 26'th Feb 2026
$1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year ‑ over ‑ year growth
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
12:30am, Thursday, 26'th Feb 2026
Study met primary endpoint (p-value = 0.012) First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics
argenx to Present at TD Cowen 46th Annual Healthcare Conference
01:00am, Monday, 23'rd Feb 2026
February 23, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, tod
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 6,782 Shares of argenex SE $ARGX
06:54am, Friday, 20'th Feb 2026
BNP PARIBAS ASSET MANAGEMENT Holding S.A. reduced its holdings in argenex SE (NASDAQ: ARGX) by 7.8% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange C
Fiera Capital Corp Boosts Stock Position in argenex SE $ARGX
06:10am, Friday, 20'th Feb 2026
Fiera Capital Corp raised its holdings in argenex SE (NASDAQ: ARGX) by 12.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. T
Aberdeen Group plc Trims Stock Holdings in argenex SE $ARGX
03:16am, Monday, 16'th Feb 2026
Aberdeen Group plc lowered its stake in shares of argenex SE (NASDAQ: ARGX) by 5.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Co
HRMY vs. ARGX: Which Stock Is the Better Value Option?
12:41pm, Wednesday, 11'th Feb 2026
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and argenex SE (ARGX). But which of these two companies is
Artisan Global Opportunities Fund Q4 2025 Portfolio Update
09:39am, Thursday, 29'th Jan 2026
Among our top contributors in Q4 were Argenx, Lam Research and Insmed. Among our biggest detractors in Q4 were Oracle, Netflix and BAE Systems. During the quarter, we initiated new positions in RTX (R
Alta Wealth Advisors LLC Makes New $623,000 Investment in argenex SE $ARGX
03:38am, Tuesday, 27'th Jan 2026
Alta Wealth Advisors LLC purchased a new stake in argenex SE (NASDAQ: ARGX) during the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 845 shares of
HRMY or ARGX: Which Is the Better Value Stock Right Now?
12:40pm, Monday, 26'th Jan 2026
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or argenex SE (ARGX). But which of these two stocks
January 13, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimm
argenx SE (ARGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:06pm, Monday, 12'th Jan 2026
argenx SE (ARGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
